Life-style and metformin for the prevention of endometrial pathology in postmenopausal women
- PMID: 22946682
- DOI: 10.3109/09513590.2012.706671
Life-style and metformin for the prevention of endometrial pathology in postmenopausal women
Abstract
In western women, the endometrium is frequently exposed, even after menopause, to the endogenous hormonal stimulation. Such a stimulation increases the risk of pathologic conditions such as endometrial hyperplasia and type I (endometrioid) endometrial adenocarcinoma. Metabolic syndrome, obesity, insulin resistance and type II diabetes promote the endometrial stimulation, and are recognized risk factors for endometrial cancer. Furthermore, chronic hyperinsulinemia linked both to obesity and metabolic syndrome influences endometrial proliferation through direct and indirect actions. Intentional weight loss, calorie restriction and physical activity are associated with a reduced risk of the endometrial pathology. Biological mechanisms include reduction in insulin and sex steroid hormone levels. In addition to life-style modifications, the antidiabetic metformin may be proposed as preventive agent. Metformin reduces the metabolic syndrome, lowers insulin and testosterone levels in postmenopausal women, and it is a potent inhibitor of endometrial cancer cell proliferation.
Similar articles
-
Ovarian stromal hyperplasia and ovarian vein steroid levels in relation to endometrioid endometrial cancer.BJOG. 2003 Jul;110(7):690-5. BJOG. 2003. PMID: 12842061
-
Endometrial patterns and endocrinologic characteristics of asymptomatic menopausal women.Gynecol Endocrinol. 2001 Feb;15(1):63-7. Gynecol Endocrinol. 2001. PMID: 11293927
-
Papillary proliferation of the endometrium: a clinicopathologic study of 59 cases of simple and complex papillae without cytologic atypia.Am J Surg Pathol. 2013 Feb;37(2):167-77. doi: 10.1097/PAS.0b013e318272d428. Am J Surg Pathol. 2013. PMID: 23211295
-
Histopathology of endometrial hyperplasia and endometrial carcinoma: an update.Ann Diagn Pathol. 2007 Aug;11(4):297-311. doi: 10.1016/j.anndiagpath.2007.05.002. Ann Diagn Pathol. 2007. PMID: 17630117 Review.
-
Endometrial carcinoma tumorigenesis and pharmacotherapy research.Minerva Endocrinol. 2012 Jun;37(2):117-32. Minerva Endocrinol. 2012. PMID: 22691886 Review.
Cited by
-
Long-term alcohol intake and risk of endometrial cancer in the Nurses' Health Study, 1980-2010.Br J Cancer. 2014 Jul 8;111(1):186-94. doi: 10.1038/bjc.2014.257. Epub 2014 May 22. Br J Cancer. 2014. PMID: 24853180 Free PMC article.
-
Metformin for endometrial hyperplasia.Cochrane Database Syst Rev. 2017 Oct 27;10(10):CD012214. doi: 10.1002/14651858.CD012214.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2024 May 2;5:CD012214. doi: 10.1002/14651858.CD012214.pub3 PMID: 29077194 Free PMC article. Updated. Review.
-
Metformin for endometrial hyperplasia.Cochrane Database Syst Rev. 2024 May 2;5(5):CD012214. doi: 10.1002/14651858.CD012214.pub3. Cochrane Database Syst Rev. 2024. PMID: 38695827 Review.
-
Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia.J Gynecol Oncol. 2014 Jul;25(3):214-20. doi: 10.3802/jgo.2014.25.3.214. Epub 2014 Jul 3. J Gynecol Oncol. 2014. PMID: 25045434 Free PMC article. Clinical Trial.
-
Metformin-Treatment Option for Social Impairment? An Open Clinical Trial to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior.Life (Basel). 2022 Jul 5;12(7):998. doi: 10.3390/life12070998. Life (Basel). 2022. PMID: 35888087 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
